SEARCH

SEARCH BY CITATION

References

  • 1
    Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol2007;2:5439.
  • 2
    Kovacs KJ. c-Fos as a transcription factor: a stressful (re)view from a functional map. Neurochem Int1998;33:28797.
  • 3
    Piechaczyk M, Blanchard JM. c-fos proto-oncogene regulation and function. Crit Rev Oncol Hematol1994;17:93131.
  • 4
    Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep2006;58(Suppl):6974.
  • 5
    McCarthy AL, Woolfson RG, Raju SK, Poston L. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol1993;168:132330.
  • 6
    Cockell AP, Poston L. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension1997;30:24751.
  • 7
    Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA2001;285:160712.
  • 8
    Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation2010;122:47887.
  • 9
    Khan F, Belch JJ, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension2005;46:11238.
  • 10
    Myers J, Mires G, MacLeod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension2005;45:25863.
  • 11
    Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol2002;187:168693.
  • 12
    Faas MM, van Pampus MG, Anninga ZA, Salomons J, Westra IM, Donker RB, et al.Plasma from preeclamptic women activates endothelial cells via monocyte activation in vitro. J Reprod Immunol2010;1987:2838.
  • 13
    Faas MM, Donker RB, van Pampus MG, Huls AM, Salomons J, de Vos P, et al.Plasma of pregnant and preeclamptic women activates monocytes in vitro. Am J Obstet Gynecol2008;199:848.
  • 14
    Donker RB, Asgeirsdottir SA, Gerbens F, van Pampus MG, Kallenberg CG, te Meerman GJ, et al.Plasma factors in severe early-onset preeclampsia do not substantially alter endothelial gene expression in vitro. J Soc Gynecol Investig2005;12:98106.
  • 15
    Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J, et al.Urinary proteomics for prediction of preeclampsia. Hypertension2011;57:5619.
  • 16
    Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ2005;330:565.
  • 17
    Brown MA, Lindheimer MD, De Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy2001;20:IXXIV.
  • 18
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods2001;25:4028.
  • 19
    Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett2004;573:8392.
  • 20
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol1995;57:289300.
  • 21
    Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, Ziche M, et al.c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA1999;96:96716.
  • 22
    Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol2002;4:E1316.
  • 23
    Reynolds LP, Redmer DA. Angiogenesis in the placenta. Biol Reprod2001;64:103340.
  • 24
    Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al.First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab2004;89:7705.
  • 25
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest2003;111:64958.
  • 26
    Carty DM, Anderson LA, Freeman DJ, Welsh PI, Brennand JE, Dominiczak AF, et al.Early pregnancy soluble E-selectin concentrations and risk of preeclampsia. J Hypertens2012;30:9549.
  • 27
    Marzioni D, Todros T, Cardaropoli S, Rolfo A, Lorenzi T, Ciarmela P, et al.Activating protein-1 family of transcription factors in the human placenta complicated by preeclampsia with and without fetal growth restriction. Placenta2010;31:91927.
  • 28
    Faxen M, Nasiell J, Lunell NO, Blanck A. Differences in mRNA expression of endothelin-1, c-fos and c-jun in placentas from normal pregnancies and pregnancies complicated with preeclampsia and/or intrauterine growth retardation. Gynecol Obstet Invest1997;44:936.
  • 29
    Kang JH, Song H, Yoon JA, Park DY, Kim SH, Lee KJ, et al.Preeclampsia leads to dysregulation of various signaling pathways in placenta. J Hypertens2011;29:92836.
  • 30
    Winn VD, Gormley M, Fisher SJ. The Impact of Preeclampsia on Gene Expression at the Maternal-Fetal Interface. Pregnancy Hypertens2011;1:1008.
  • 31
    Stewart FM, Freeman DJ, Ramsay JE, Greer IA, Caslake M, Ferrell WR. Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers. J Clin Endocrinol Metab2007;92:96975.
  • 32
    Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al.Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension2010;56:7419.